2[2]Avery GB,Fletcher MA,MacDonald MG.Neonatology pathophysiology & management of the newborn.5th ed.Philadelphia:Lippincott Williams & Wilkins,1999.509
3[5]Lyon A.Chronic lung disease of prematurity:the role of intra-uterine infection.Eur J Pediatr,2000,159:798
4[6]De Dooy JJ,Mahieu LM,Van Bever HP.The role of inflammation in the development of chronic lung disease in neonates.Eur J Pediatr,2001,160:457
5[8]Halliday HL,Ehrenkranz RA,Doyle LW.Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants.Cochrane Database Syst Rev,2003(1):CD001145
6[9]Groneck P.Perinatal glucocorticosteroid therapy:time for reconsideration.Z Geburtshilfe Neonatol,2001,205(6):231
7[10]LeFlore JL,Salhab WA,Broyles RS,et al.Association of antenatal and postnatal dexamethasone exposure with outcomes in extremely low birth weight neonates.Pediatrics,2002,110(2 Pt 1):275
8[1]Dik WA,Krijger R R,Bonekamp L,et al.Localization and potential role of matrix metalloproteinase-1 and tissue inhibitors of metalloproteinase-1 and -2 in different phases of bronchopulmonary dysplasia.Pediatr Res,2001,50(6):761
9[2]Schock BC,Sweet DG,Ennis M,et al.Oxidative stress and increased type collagenase levels in bronchoalveolar lavage fluid from newborn babies.Pediatr Res,2001,50(1):29
10[3]Kheradmand F,Rishi K,Werb Z.Signaling through the EGF receptor controls lung morphogenesis in part by regulating MT1-MMP-mediated activation of gelatinase A/MMP2.J Cell Sci,2002,115(4):839
4Doyle LW, Halliday HL, Ehrenkranz RA, et al. Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics, 2005,115: 655-661.
